Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 47.00 46.00 48.00 47.00 47.00 47.00 12,112 07:36:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -24.1 -18.9 - 49

Verona Pharma plc Result Of Agm

07/05/2019 12:52pm

UK Regulatory (RNS & others)


 
TIDMVRP 
 
   LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, announces that all resolutions 
proposed at the Annual General Meeting held today were duly passed. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Ensifentrine is currently in Phase 2b 
clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma may also develop ensifentrine for the treatment of cystic 
fibrosis and asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                         Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer              info@veronapharma.com 
Victoria Stewart, Director of Communications 
 
N+1 Singer                                                Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
 Aubrey Powell /Jen Boorer /Iqra Amin (Corporate 
 Finance) Brough Ransom /Mia Gardner (Corporate Broking) 
 
Optimum Strategic Communications                          Tel: +44 (0) 203 922 0891 
 (European Media and Investor enquiries)                   verona@optimumcomms.com 
Mary Clark, Anne Marieke Ezendam, Hollie Vile 
 
 
 
 
 
 

(END) Dow Jones Newswires

May 07, 2019 07:52 ET (11:52 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Verona Pharma Chart

1 Year Verona Pharma Chart

1 Month Verona Pharma Chart

1 Month Verona Pharma Chart
Your Recent History
LSE
VRP
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191022 17:12:28